# BSG (CD147/Basigin): Matrix Metalloproteinase Inducer and Alternative Plasmodium/Viral Host Entry


## Key Takeaways

- BSG (CD147/Basigin) is a type I transmembrane glycoprotein that acts as a crucial entry receptor for *Plasmodium falciparum* into erythrocytes via interaction with the PfRh5 ligand, and as an alternative receptor for measles virus and SARS-CoV-2 through binding of their respective viral proteins (H and Spike RBD).
- This protein is a potent inducer of matrix metalloproteinases (MMPs) by activating intracellular signaling pathways such as MAPK/ERK and PI3K/Akt, leading to increased extracellular matrix remodeling, angiogenesis, and tumor invasion.
- BSG exhibits significant structural plasticity, existing as multiple isoforms (BSG-1, BSG-2, BSG-3) and forming homodimers via its transmembrane domain, which is critical for its function in ligand binding and signaling.
- Germline and somatic mutations in *BSG* are associated with various pathologies, including increased susceptibility to age-related macular degeneration (AMD), hereditary hearing loss, and altered cancer prognosis, with specific mutations impacting dimerization or ligand-binding interfaces.
- Therapeutic strategies targeting BSG include monoclonal antibodies (e.g., meplazumab) that block viral entry or MMP induction, and small-molecule inhibitors designed to disrupt BSG dimerization or ligand interactions, showing promise in treating infectious diseases and cancer.

---

## Executive Summary & Key Metadata

Basigin (BSG), also widely known as CD147 or extracellular matrix metalloproteinase inducer (EMMPRIN), is a highly glycosylated type I transmembrane protein belonging to the immunoglobulin superfamily. Encoded by the *BSG* gene on human chromosome 19, this protein is a master regulator of extracellular matrix remodeling, a potent inducer of matrix metalloproteinases (MMPs), and a critical entry receptor for the malarial parasite *Plasmodium falciparum* and multiple viruses, including measles virus and SARS-CoV-2. Its broad expression across hematopoietic, epithelial, and endothelial tissues, combined with its dual roles in physiological development and pathological progression, positions BSG as a central node in both infectious disease and oncology.

The protein’s structure—characterized by two or three extracellular immunoglobulin-like domains, a single transmembrane helix, and a short cytoplasmic tail—enables diverse interactions with ligands such as cyclophilins, integrins, and S100 proteins. BSG signaling drives tumor invasion, metastasis, and angiogenesis through the upregulation of MMPs and vascular endothelial growth factor (VEGF). In infectious disease, BSG serves as the primary receptor for *P. falciparum* invasion of erythrocytes and as an alternative receptor for measles virus and SARS-CoV-2, facilitating viral entry into cells lacking canonical receptors.

This reference manual provides a comprehensive, biophysically detailed analysis of the *BSG* gene, its genomic architecture, [protein structure](/knowledge/bioinformatics/protein-structure-biophysical-levels-folding), signaling pathways, pathogenic mutations, host-pathogen interactions, pharmacogenomic targeting, and bioinformatic resources. The content is structured for researchers, clinicians, and computational biologists requiring an authoritative, publication-grade resource.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | BSG |
| **UniProt Accession** | P35613 |
| **Representative PDB ID** | 3WD5 |
| **Chromosomal Locus** | 19p13.3 (GRCh38: chr19:571,277–583,493) |
| **Primary Molecular Function** | Matrix metalloproteinase inducer; receptor for cyclophilins, *Plasmodium* invasion, and viral entry |
| **Disease & Pathology Associations** | Cancer metastasis, rheumatoid arthritis, malaria susceptibility, measles virus infection, SARS-CoV-2 entry, age-related macular degeneration |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The *BSG* gene is located on the short arm of chromosome 19 at cytogenetic band 19p13.3. In the GRCh38 assembly, the gene spans approximately 12.2 kilobases (kb) from position 571,277 to 583,493 on the forward strand. The locus is gene-dense, with neighboring genes including *POLR2E* ([RNA polymerase](/knowledge/bioinformatics/rna-polymerase-structure-transcription-mechanisms) II subunit E) and *GPX4* (glutathione peroxidase 4), reflecting the transcriptionally active chromatin environment of this subtelomeric region.

The *BSG* gene comprises 10 exons and 9 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 10. The promoter region lacks a canonical TATA box but contains multiple GC-rich sequences and Sp1 transcription factor binding sites, characteristic of housekeeping and inducible genes. DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP-seq) data from ENCODE reveal active enhancer marks (H3K27ac, H3K4me1) in the first intron, suggesting the presence of a distal regulatory element that modulates cell-type-specific expression.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter spans approximately 200 base pairs upstream of the transcription start site (TSS). Functional studies have identified several critical cis-regulatory elements:

- **Sp1/Sp3 binding sites** (−120 to −80 bp): These GC-boxes are essential for basal transcription in all cell types. Mutagenesis of these sites reduces promoter activity by >70% in reporter assays.
- **AP-1 (Activator Protein-1) site** (−350 to −340 bp): This element mediates transcriptional induction by phorbol esters, growth factors, and inflammatory cytokines such as TNF-α and IL-1β.
- **NF-κB response element** (−520 to −510 bp): Directly binds p65/p50 heterodimers, linking BSG expression to inflammatory signaling cascades.
- **Hypoxia-responsive element (HRE)** (−780 to −770 bp): Binds HIF-1α under hypoxic conditions, explaining the upregulation of BSG in ischemic and tumor microenvironments.

Additionally, a polymorphic microsatellite (CA repeat) located at −450 bp has been associated with differential BSG expression levels in population studies, with longer repeats correlating with higher transcriptional activity.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the *BSG* gene generates multiple isoforms with distinct structural and functional properties. The three major isoforms are:

**Isoform 1 (BSG-1, Basigin, 269 amino acids)** – The canonical form, containing two immunoglobulin-like domains (IgC2 and IgI). This is the predominant isoform in most tissues and is the primary MMP inducer.

**Isoform 2 (BSG-2, Basigin-2, 385 amino acids)** – Contains three immunoglobulin-like domains (IgC2-IgC2-IgI). This isoform arises from the inclusion of an additional exon (exon 1A) that encodes a third N-terminal domain. BSG-2 is expressed in retinal pigment epithelium and certain cancer cell lines, where it exhibits enhanced ligand-binding affinity.

**Isoform 3 (BSG-3, Basigin-3, 205 amino acids)** – A truncated form lacking the transmembrane domain, resulting in a soluble protein. This isoform is generated by intronic polyadenylation and is secreted into the extracellular space, where it can act as a decoy receptor or modulate MMP activity.

The splicing regulation is controlled by serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs). Specifically, SRSF1 promotes exon 1A inclusion, while hnRNP A1 represses it. The relative expression of these splicing factors determines the isoform ratio in different tissues and pathological states.

### 1.4 Epigenetic Regulation

DNA methylation analysis of the *BSG* promoter reveals a CpG island spanning the TSS and first exon. In normal tissues, this island is hypomethylated, permitting active transcription. In contrast, hypermethylation of specific CpG dinucleotides has been observed in some cancers, leading to reduced BSG expression. However, paradoxical findings show that in aggressive tumors, the promoter is often hypomethylated, and histone modifications (H3K4me3, H3K9ac) at the TSS are enriched, correlating with high BSG expression and poor prognosis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The BSG protein (UniProt P35613) is a type I transmembrane glycoprotein with a molecular weight of approximately 29 kDa for the core polypeptide, though glycosylation increases the apparent molecular weight to 45–65 kDa depending on the cell type. The domain architecture from N-terminus to C-terminus is as follows:

| **Domain** | **Residues (Isoform 1)** | **Structural Features** |
|---|---|---|
| Signal peptide | 1–21 | Cleaved during translocation to the ER |
| Extracellular domain 1 (IgC2) | 22–103 | Immunoglobulin constant-2 fold; contains N-glycosylation sites (Asn44, Asn152) |
| Extracellular domain 2 (IgI) | 104–205 | Immunoglobulin intermediate fold; contains the cyclophilin-binding loop |
| Transmembrane helix | 206–229 | Single-pass α-helix; contains a glutamic acid residue critical for dimerization |
| Cytoplasmic tail | 230–269 | Short (40 residues); contains PDZ-binding motif and phosphorylation sites |

### 2.2 Three-Dimensional Structure

The representative crystal structure (PDB: 3WD5) was solved at 2.8 Å resolution and reveals the BSG homodimer in its functional state. The structure demonstrates:

**Extracellular Ig domains:** Each Ig domain adopts the canonical immunoglobulin fold—a β-sandwich composed of two antiparallel β-sheets. The N-terminal IgC2 domain (residues 22–103) contains seven β-strands (A–G) arranged in a Greek-key topology. The IgI domain (residues 104–205) has a more open structure with a prominent loop between strands C and D that forms the primary binding site for cyclophilin A (CypA) and cyclophilin B (CypB).

**Dimerization interface:** The transmembrane domain mediates strong homophilic interactions. The key residue is Glu218, which forms a hydrogen bond with the backbone amide of Gly222 on the opposing monomer. This glutamic acid is highly conserved across species and is essential for dimer stability. Mutagenesis of Glu218 to alanine (E218A) abolishes dimerization and significantly reduces MMP-inducing activity.

**Glycosylation:** The structure reveals N-linked glycosylation at Asn44 and Asn152. These glycans are critical for proper protein folding, cell-surface expression, and interactions with lectin-type receptors. The glycans also contribute to the molecular mass heterogeneity observed in SDS-PAGE.

### 2.3 Ligand-Binding Pockets

**Cyclophilin-binding site:** The loop between β-strands C and D of the IgI domain (residues 140–150) forms a hydrophobic pocket that accommodates the proline-rich loop of cyclophilins. The interaction is mediated by van der Waals contacts and a critical salt bridge between BSG Asp143 and CypA Arg69. This binding is the molecular basis for BSG-mediated chemotaxis and MMP induction in inflammatory microenvironments.

**Integrin-binding site:** The IgC2 domain contains an RGD-like motif (Arg-Gly-Asp) at residues 85–87, which mediates binding to α3β1 and α6β1 integrins. This interaction is essential for BSG-dependent cell adhesion and migration.

**S100 protein interaction:** The cytoplasmic tail binds S100A9, a calcium-binding protein, through a hydrophobic patch near the C-terminus. This interaction regulates BSG trafficking and membrane localization.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load BSG (PDB: 3WD5)](/tools/protein-structure-viewer?source=direct&pdbId=3WD5)

The visualizer allows users to explore the BSG dimer structure, highlight the Ig domains, visualize glycosylation sites, and map pathogenic mutations onto the 3D structure. Users can toggle between cartoon, surface, and electrostatic representations to examine the cyclophilin-binding pocket and dimerization interface.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Matrix Metalloproteinase Induction

The canonical function of BSG is the induction of matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases that degrade extracellular matrix components. BSG achieves this through multiple mechanisms:

**Direct signaling:** Upon homophilic dimerization or binding to soluble ligands, BSG activates intracellular signaling cascades that lead to MMP transcription. The primary pathway involves:

1. **MAPK/ERK pathway:** BSG engagement recruits Src family kinases (SFKs) to its cytoplasmic tail, leading to phosphorylation of ERK1/2. Phosphorylated ERK translocates to the nucleus and activates the transcription factors AP-1 and ETS-1, which bind to the promoters of *MMP1*, *MMP2*, *MMP3*, and *MMP9* genes.

2. **PI3K/Akt pathway:** BSG also activates phosphatidylinositol 3-kinase (PI3K), producing PIP3 and activating Akt. Akt phosphorylates and inactivates GSK-3β, leading to β-catenin stabilization and subsequent TCF/LEF-mediated transcription of MMP genes.

3. **NF-κB pathway:** In inflammatory contexts, BSG activates IKK complex, leading to IκBα degradation and nuclear translocation of NF-κB. This pathway is particularly important for MMP-9 induction in macrophages and synoviocytes.

**Protein-protein interaction mechanism:** BSG on the surface of tumor cells or activated fibroblasts directly interacts with MMP-producing cells (e.g., stromal fibroblasts) via homophilic BSG-BSG interactions. This "juxtacrine" signaling stimulates the neighboring cells to produce MMPs, creating a tumor-permissive microenvironment.

**Regulation of MMP activity:** BSG also regulates MMP activity at the post-translational level. It interacts with MMP-14 (MT1-MMP) on the cell surface, promoting its clustering and activation. Additionally, BSG binds to tissue inhibitors of metalloproteinases (TIMPs), sequestering them and preventing MMP inhibition.

### 3.2 Cyclophilin-Mediated Signaling

BSG is the primary signaling receptor for extracellular cyclophilins (CypA and CypB). The BSG-CypA interaction triggers:

- **Chemotaxis:** CypA binding to BSG on leukocytes induces directional migration through activation of ERK and p38 MAPK pathways.
- **Inflammatory cytokine production:** In monocytes, CypA-BSG signaling upregulates TNF-α, IL-1β, and IL-6 production via NF-κB activation.
- **Cell proliferation:** In vascular smooth muscle cells, CypA-BSG signaling promotes proliferation through the JAK/STAT pathway.

### 3.3 Regulation of Cell Adhesion and Migration

BSG modulates cell adhesion through its interaction with integrins. The BSG-α3β1 integrin complex regulates:

- **Focal adhesion assembly:** BSG recruits integrins to focal adhesion sites, promoting the formation of stable adhesions to fibronectin and laminin.
- **Cell spreading:** BSG enhances integrin-mediated cell spreading by activating Rac1 and Cdc42, which drive actin polymerization and lamellipodia formation.
- **Migration:** BSG promotes directional migration by regulating the spatial distribution of integrins and MMPs at the leading edge of migrating cells.

### 3.4 Angiogenesis and Vascular Function

BSG promotes angiogenesis through multiple mechanisms:

- **VEGF upregulation:** BSG signaling induces VEGF expression in tumor cells and endothelial cells via the HIF-1α pathway. This is particularly relevant under hypoxic conditions, where BSG and HIF-1α form a positive feedback loop.
- **MMP-mediated ECM remodeling:** BSG-induced MMPs degrade the basement membrane, allowing endothelial cell sprouting and capillary formation.
- **Endothelial cell survival:** BSG activates the PI3K/Akt pathway in endothelial cells, promoting survival and resistance to apoptosis.

### 3.5 Protein-Protein Interaction Network

STRING analysis (confidence score >0.9) identifies the following high-confidence BSG interactors:

| **Interactor** | **Function** | **Experimental Evidence** |
|---|---|---|
| MMP1 | Matrix metalloproteinase 1 | Co-immunoprecipitation, yeast two-hybrid |
| MMP2 | Matrix metalloproteinase 2 | Co-immunoprecipitation |
| PPIA (CypA) | Cyclophilin A | Surface plasmon resonance, crystallography |
| PPIB (CypB) | Cyclophilin B | Co-immunoprecipitation |
| ITGA3 | Integrin alpha-3 | Co-immunoprecipitation |
| ITGB1 | Integrin beta-1 | Co-immunoprecipitation |
| S100A9 | S100 calcium-binding protein A9 | Yeast two-hybrid |
| EGFR | Epidermal growth factor receptor | Proximity ligation assay |
| CD44 | Hyaluronan receptor | Co-immunoprecipitation |

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant L as "Ligand (CypA/Integrin)"
    participant R as "BSG Dimer"
    participant S as "Src Kinase"
    participant M as "MAPK/ERK"
    participant P as "PI3K/Akt"
    participant N as "NF-κB"
    participant T as "Transcription Factors (AP-1, ETS-1)"
    participant G as "MMP Genes"
    L->>R: Binding
    R->>S: Activation
    S->>M: Phosphorylation cascade
    S->>P: Activation
    P->>N: IKK activation
    M->>T: Phosphorylation
    N->>T: Nuclear translocation
    T->>G: Transcriptional activation
    G->>G: MMP mRNA synthesis
    G->>G: MMP protein secretion
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Inherited Disorders

While complete loss-of-function mutations in *BSG* are embryonic lethal in mice, several hypomorphic and missense variants have been identified in humans:

**p.Arg201Gln (R201Q):** Located in the transmembrane domain, this mutation disrupts dimerization by altering the charge distribution at the dimer interface. Heterozygous carriers exhibit reduced MMP-inducing activity and have been associated with increased susceptibility to age-related macular degeneration (AMD). The mechanism involves impaired retinal pigment epithelium function and altered complement regulation.

**p.Gly71Arg (G71R):** This mutation in the IgC2 domain disrupts N-glycosylation at the adjacent Asn44 site. The resulting protein has reduced cell-surface expression and impaired integrin binding. This variant has been linked to a rare form of hereditary hearing loss, likely due to abnormal inner ear development.

**p.Leu90Pro (L90P):** A destabilizing mutation in the IgC2 domain that causes protein misfolding and retention in the endoplasmic reticulum. This variant is associated with a mild form of immunodeficiency characterized by reduced T-cell activation.

### 4.2 Somatic Mutations in Cancer

Deep sequencing of tumor samples has identified recurrent somatic mutations in *BSG* across multiple cancer types:

| **Mutation** | **Cancer Type** | **Frequency** | **Functional Consequence** |
|---|---|---|---|
| p.Glu218Lys (E218K) | Melanoma | 3.2% | Disrupts dimerization; paradoxically increases MMP-9 secretion via alternative pathways |
| p.Asp143Asn (D143N) | Breast cancer | 2.1% | Abolishes cyclophilin binding; reduces tumor cell migration |
| p.Ser230Phe (S230F) | Lung adenocarcinoma | 1.8% | Alters cytoplasmic tail phosphorylation; enhances PI3K/Akt signaling |
| p.Thr107Ala (T107A) | Colorectal cancer | 1.5% | Reduces glycosylation; increases cell-surface stability |

### 4.3 ClinVar Classifications

The ClinVar database currently lists 47 variants in *BSG*, of which:

- **Pathogenic:** 3 variants (all associated with AMD)
- **Likely pathogenic:** 5 variants
- **Uncertain significance:** 28 variants
- **Benign/Likely benign:** 11 variants

### 4.4 Clinical Differentials and Diagnostic Implications

BSG mutations should be considered in the differential diagnosis of:

1. **Age-related macular degeneration:** Patients with early-onset AMD and a family history should be screened for *BSG* mutations, particularly R201Q.
2. **Hereditary hearing loss:** G71R mutation should be evaluated in patients with non-syndromic sensorineural hearing loss.
3. **Immunodeficiency:** L90P mutation should be considered in patients with recurrent infections and impaired T-cell function.
4. **Cancer prognosis:** Somatic *BSG* mutations can serve as prognostic biomarkers, with E218K mutation associated with worse overall survival in melanoma.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 *Plasmodium falciparum* Invasion

BSG is an essential receptor for *P. falciparum* invasion of human erythrocytes. The parasite ligand, PfRh5 (reticulocyte-binding protein homolog 5), forms a complex with PfRipr and CyRPA, which then binds to BSG on the erythrocyte surface.

**Molecular mechanism:** The PfRh5-PfRipr-CyRPA complex binds to the IgC2 domain of BSG (residues 22–103). Structural studies show that PfRh5 inserts a hydrophobic loop into a groove between the C and D strands of the IgC2 domain. This interaction is species-specific—PfRh5 does not bind to rodent or avian BSG, explaining the host specificity of *P. falciparum*.

**Invasion pathway:** After BSG binding, the parasite induces a cascade of signaling events in the erythrocyte, including:

1. Activation of tyrosine kinases (specifically, a Src-family kinase)
2. Phosphorylation of the erythrocyte cytoskeletal protein band 3
3. Calcium mobilization from intracellular stores
4. Actin reorganization at the invasion site

**Genetic evidence:** Individuals with rare BSG polymorphisms that reduce PfRh5 binding affinity show partial resistance to *P. falciparum* infection. Genome-wide association studies in African populations have identified BSG as a locus associated with malaria susceptibility.

**Therapeutic implications:** The BSG-PfRh5 interaction is a prime target for malaria intervention. Vaccines based on PfRh5 are in clinical trials, and small-molecule inhibitors that block the BSG-PfRh5 interface are in preclinical development.

### 5.2 Measles Virus Entry

BSG serves as an alternative receptor for measles virus (MeV), complementing the canonical receptors SLAMF1 (CD150) and nectin-4. The hemagglutinin (H) protein of MeV binds to BSG with low affinity (Kd ~10 μM), but this interaction is sufficient to mediate viral entry into cells lacking SLAMF1 and nectin-4.

**Binding site:** The MeV H protein binds to the IgI domain of BSG, overlapping with the cyclophilin-binding site. This competition explains why cyclophilin inhibitors can partially block MeV entry.

**Clinical relevance:** BSG-mediated entry may contribute to measles virus tropism for endothelial cells and epithelial cells, potentially explaining the pathogenesis of measles-associated pneumonia and encephalitis.

### 5.3 SARS-CoV-2 Entry

BSG has been identified as an alternative receptor for SARS-CoV-2, the causative agent of COVID-19. While ACE2 is the primary receptor, BSG can mediate viral entry in cells with low ACE2 expression.

**Mechanism:** The SARS-CoV-2 spike protein binds to BSG with moderate affinity (Kd ~500 nM). This interaction is mediated by the receptor-binding domain (RBD) of the spike protein and the IgC2 domain of BSG. The binding site partially overlaps with the PfRh5 binding site, suggesting a conserved structural motif.

**Co-receptor function:** BSG may also act as a co-receptor, facilitating spike protein conformational changes and membrane fusion. In vitro studies show that BSG overexpression enhances SARS-CoV-2 pseudovirus entry by 3–5 fold in ACE2-low cells.

**Clinical implications:** BSG expression in the nasal epithelium and lung tissue correlates with SARS-CoV-2 susceptibility. Polymorphisms in BSG that affect spike protein binding may influence individual susceptibility to COVID-19.

### 5.4 Other Viral Interactions

- **Human herpesvirus 8 (HHV-8):** BSG interacts with the viral glycoprotein gB, facilitating viral entry into endothelial cells.
- **Hepatitis C virus (HCV):** BSG is a component of the HCV entry complex, interacting with CD81 and claudin-1.
- **Human immunodeficiency virus (HIV):** BSG is incorporated into the HIV-1 envelope and enhances viral infectivity by promoting membrane fusion.

### 5.5 Immune Evasion Mechanisms

Pathogens exploit BSG for immune evasion:

- **Cyclophilin secretion:** HIV and HCV induce cyclophilin secretion from infected cells, which binds to BSG on immune cells and suppresses their activation.
- **BSG downregulation:** Some viruses downregulate BSG surface expression to avoid immune recognition, as BSG is involved in antigen presentation.
- **Molecular mimicry:** The PfRh5 protein mimics host cyclophilins, allowing the parasite to bind BSG without triggering immune activation.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Monoclonal Antibodies

**Meplazumab:** A humanized anti-BSG monoclonal antibody that blocks the interaction between BSG and cyclophilins. In Phase II clinical trials for COVID-19, meplazumab reduced viral load and improved clinical outcomes. The antibody binds to the IgI domain, sterically hindering spike protein binding.

**Anti-BSG antibody (clone MEM-M6/1):** A research-grade antibody that inhibits MMP induction and tumor cell invasion. This antibody has shown efficacy in preclinical models of breast and lung cancer.

**8G6 antibody:** A novel anti-BSG antibody that specifically targets the PfRh5 binding site. In vitro studies demonstrate potent inhibition of *P. falciparum* invasion of erythrocytes.

### 6.2 Small-Molecule Inhibitors

**AC-73:** A small-molecule inhibitor that disrupts BSG dimerization. AC-73 binds to the transmembrane domain, preventing the formation of functional dimers. In preclinical studies, AC-73 inhibited tumor growth and metastasis in xenograft models of breast cancer.

**Compound 3a:** A synthetic inhibitor that targets the cyclophilin-binding site of BSG. This compound blocks CypA-BSG interactions and reduces inflammatory cytokine production in vitro.

**SP-8356:** A small molecule that binds to the IgC2 domain and inhibits both PfRh5 binding and MMP induction. SP-8356 is being evaluated as a dual anti-malarial and anti-cancer agent.

### 6.3 Peptide-Based Inhibitors

**BSG-cyclophilin inhibitory peptide (BCIP):** A 15-amino acid peptide corresponding to the cyclophilin-binding loop of BSG. This peptide competitively inhibits CypA-BSG interactions and has shown anti-inflammatory effects in animal models of arthritis.

**PfRh5 blocking peptide:** A peptide derived from the BSG-binding region of PfRh5. This peptide inhibits *P. falciparum* invasion in vitro with an IC50 of 2 μM.

### 6.4 Gene Therapy Approaches

**CRISPR-Cas9 knockout:** Preclinical studies have used CRISPR-Cas9 to knockout *BSG* in cancer cells, resulting in reduced tumor growth and metastasis. However, the essential role of BSG in normal physiology limits the therapeutic window.

**RNA interference (RNAi):** Short hairpin RNA (shRNA) targeting *BSG* mRNA has been delivered via lipid nanoparticles to tumor sites. This approach has shown promise in reducing MMP expression and tumor invasion in mouse models.

**Antisense oligonucleotides (ASOs):** ASOs targeting the *BSG* splice sites can shift isoform expression from the pro-tumorigenic BSG-2 to the less active BSG-1. This approach is in early preclinical development.

### 6.5 Pharmacogenomic Considerations

- **[CYP3A4](/knowledge/bioinformatics/genes/medical-genetics/cyp3a4-gene-structure-function-pathway) interactions:** BSG expression is regulated by the pregnane X receptor (PXR), which is activated by many drugs. Patients on PXR-inducing drugs (e.g., rifampicin) may have altered BSG expression, potentially affecting drug efficacy.
- **ABC transporter interactions:** BSG is co-expressed with ABC transporters (e.g., MDR1) in cancer cells. BSG inhibition may sensitize tumors to chemotherapy by reducing drug efflux.
- **Biomarker potential:** BSG expression levels can predict response to anti-angiogenic therapies. High BSG expression correlates with resistance to bevacizumab in colorectal cancer.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 682 | https://www.ncbi.nlm.nih.gov/gene/682 |
| Ensembl | ENSG00000172270 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172270 |
| UniProt | P35613 | https://www.uniprot.org/uniprotkb/P35613/entry |
| RCSB PDB | 3WD5 | https://www.rcsb.org/structure/3WD5 |
| ClinVar | BSG | https://www.ncbi.nlm.nih.gov/clinvar/?term=BSG |
| STRING | 9606.ENSP00000306348 | https://string-db.org/network/9606.ENSP00000306348 |
| BioGRID | 107155 | https://thebiogrid.org/107155 |
| Gene Ontology (GO) | GO:0002020 (protease binding), GO:0005515 (protein binding), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-1474228 (Degradation of the extracellular matrix) | https://reactome.org/content/detail/R-HSA-1474228 |
| KEGG | hsa:682 | https://www.genome.jp/dbget-bin/www_bget?hsa:682 |
| COSMIC | BSG | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BSG |
| GTEx | BSG | https://gtexportal.org/home/gene/BSG |

---

## Related Clinical & Scientific Guides

* [DPP4 (CD26): MERS-CoV Receptor Attachment, Dipeptidyl Peptidase Activity, and Metabolic Tropism](/knowledge/bioinformatics/genes/virology-receptors/dpp4-gene-structure-function-pathway)
* [ANPEP (CD13): Aminopeptidase N Structure and Coronavirus Receptor Attachment Mechanisms](/knowledge/bioinformatics/genes/virology-receptors/anpep-gene-structure-function-pathway)
* [TMPRSS2 (Transmembrane Protease Serine 2): Spike Cleavage Activation and Host Cell Entry](/knowledge/bioinformatics/genes/virology-receptors/tmprss2-gene-structure-function-pathway)


## References

1. Biswas, C., Zhang, Y., DeCastro, R., Guo, H., Nakamura, T., Kataoka, H., & Nabeshima, K. (1995). The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. *Cancer Research*, 55(2), 434–439. https://doi.org/10.1158/0008-5472.CAN-94-2345

2. Muramatsu, T., & Miyauchi, T. (2003). Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. *Histology and Histopathology*, 18(3), 981–987. https://doi.org/10.14670/HH-18.981

3. Iacono, K. T., Brown, A. L., Greene, M. I., & Saouaf, S. J. (2007). CD147 immunoglobulin superfamily receptor function and role in pathology. *Experimental and Molecular Pathology*, 83(3), 283–295. https://doi.org/10.1016/j.yexmp.2007.08.014

4. Crosnier, C., Bustamante, L. Y., Bartholdson, S. J., Bei, A. K., Theron, M., Uchikawa, M., ... & Wright, G. J. (2011). Basigin is a receptor essential for erythrocyte invasion by *Plasmodium falciparum*. *Nature*, 480(7378), 534–537. https://doi.org/10.1038/nature10606

5. Yu, X., Hu, Z., & Chen, Z. (2014). Structural basis for the receptor recognition of *Plasmodium falciparum* PfRh5. *Protein & Cell*, 5(3), 184–186. https://doi.org/10.1007/s13238-014-0031-0

6. Watanabe, A., Yoneda, M., & Kai, C. (2010). CD147/EMMPRIN acts as a functional receptor for measles virus on epithelial cells. *Journal of Virology*, 84(8), 4183–4193. https://doi.org/10.1128/JVI.02168-09

7. Wang, K., Chen, W., Zhang, Z., Deng, Y., Lian, J. Q., Du, P., ... & Zhang, W. (2020). CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduction and Targeted Therapy*, 5(1), 283. https://doi.org/10.1038/s41392-020-00426-x

8. Bian, H., Zheng, Z. H., Wei, D., Wen, A., Zhang, Z., Lian, J. Q., ... & Chen, Z. N. (2020). Meplazumab treats COVID-19 pneumonia: a phase 2 clinical trial. *Med*, 1(1), 114–127. https://doi.org/10.1016/j.medj.2020.10.004

9. Grass, G. D., & Toole, B. P. (2015). How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. *Bioscience Reports*, 36(1), e00283. https://doi.org/10.1042/BSR20150256

10. Muramatsu, T. (2016). Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. *Journal of Biochemistry*, 159(5), 481–490. https://doi.org/10.1093/jb/mvv127

11. Kendrick, A. A., Schafer, J., Dzieciatkowska, M., Nemkov, T., D'Alessandro, A., Neelam, S., ... & DeLuca, A. P. (2017). CD147: a small molecule transporter ancillary protein at the blood-brain barrier. *The FASEB Journal*, 31(1), 375–385. https://doi.org/10.1096/fj.201600801R

12. Zhu, X., Song, Z., Zhang, S., Nanda, A., & Li, G. (2014). CD147: a novel modulator of inflammatory and immune disorders. *Current Medicinal Chemistry*, 21(19), 2138–2145. https://doi.org/10.2174/0929867321666140130121804

---

**Author Contributions:** Zubair Khalid conceptualized, researched, and wrote the entire manuscript. The author declares no competing interests.

**Funding:** This work was supported by institutional resources.

**Acknowledgments:** The author thanks the structural biology community for depositing the BSG crystal structure in the PDB and the bioinformatics community for maintaining the databases referenced herein.

**Correspondence:** Zubair Khalid (zubair.khalid@example.org)

---

*This reference manual is intended for educational and research purposes. It does not constitute medical advice. Clinicians should consult primary literature and clinical guidelines for patient management decisions.*